TEL AVIV, Israel, May 28, 2013 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), today announced that it will be presenting at the Jefferies 2013 Global Healthcare Conference and at the ILSI-Biomed 2013 conference in June 2013.
- The Jefferies 2013 Global Healthcare Conference is being held at the Grand Hyatt Hotel in New York, New York. Yaron Daniely, Chief Executive Officer of Alcobra, is scheduled to present at 10:00 a.m. EDT on Thursday, June 6, 2013. The presentation will be broadcast over the Internet as a "live" listen only Webcast. To listen, please go to: http://www.alcobra-pharma.com/events.cfm. An archive of the event will also be available for those unable to listen live.
- The IATI Biomed 2013 Conference is being held at the David InterContinental Hotel in Tel Aviv, Israel. Dr. Daniely is scheduled to present at 4:10 p.m. IDT on Monday, June 10, 2013. The IATI Biomed 2013 conference is Israel's premier life science conference showcasing the country's most advanced companies and technologies.
About Alcobra Ltd.
Alcobra Ltd. is an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder. MG01CI has completed Phase II studies to treat Attention Deficit Hyperactivity Disorder. The company was founded in 2008 and is headquartered in Tel Aviv, Israel.
CONTACT: U.S. Investor Contacts: KCSA Strategic Communications Jeffrey Goldberger / Garth Russell +1 212.896.1249 / +1 212.896.1250 email@example.com / firstname.lastname@example.org Israel Investor Contact: Investor Relations Ltd. Moran Meir-Beres +011972-3-5167620 email@example.comSource:Alcobra Ltd.